Search alternatives:
ms decrease » _ decrease (Expand Search), mean decrease (Expand Search), use decreased (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
ms decrease » _ decrease (Expand Search), mean decrease (Expand Search), use decreased (Expand Search)
we decrease » _ decrease (Expand Search), mean decrease (Expand Search), teer decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
1261
Decreased Platelet Count in Patients Receiving Continuous Veno-Venous Hemofiltration: A Single-Center Retrospective Study
Published 2014“…<div><p>Background</p><p>A decreased platelet count may occur and portend a worse outcome in patients receiving continuous renal replacement therapy (CRRT). …”
-
1262
Compound CID 9998128 Is a Potential Multitarget Drug for Alzheimer’s Disease
Published 2018“…Moreover, the compound dose-dependently decreases β-site amyloid precursor protein cleaving enzyme (BACE-1) activity with EC<sub>50</sub> value in micromolar range. …”
-
1263
Compound CID 9998128 Is a Potential Multitarget Drug for Alzheimer’s Disease
Published 2018“…Moreover, the compound dose-dependently decreases β-site amyloid precursor protein cleaving enzyme (BACE-1) activity with EC<sub>50</sub> value in micromolar range. …”
-
1264
-
1265
Fenretinide decreases levels of PAX3/FOXO1 and its target genes in aRMS cell lines.
Published 2013“…D) Fenretinide did not decrease mRNA levels of FOXO1 in aRMS cells. qRT–PCR was carried out after treatment with an IC<sub>50</sub> concentration of fenretinide during different time points (24–48–72 hours). …”
-
1266
-
1267
Pre-treatment with CDDO-Me decreases IR-induced DNA damage in a variety of non-cancerous cells.
Published 2014“…(A) HBEC 3KT, (B) HME1, and (C) PBMCs were treated with CDDO-Me 18 hours prior to IR, then mounted on slides 30 min post-IR. …”
-
1268
-
1269
Table_1_What have we learned from a case of convalescent plasma treatment in a two-time kidney transplant recipient COVID-19 patient? A case report from the perspective of viral lo...
Published 2023“…In addition, we found evidence of an increase in antibody titers after transfusion, accompanied by a decrease in the levels of several cytokines responsible for cytokine storm.…”
-
1270
Image_1_What have we learned from a case of convalescent plasma treatment in a two-time kidney transplant recipient COVID-19 patient? A case report from the perspective of viral lo...
Published 2023“…In addition, we found evidence of an increase in antibody titers after transfusion, accompanied by a decrease in the levels of several cytokines responsible for cytokine storm.…”
-
1271
-
1272
-
1273
Sequence parameters.
Published 2023“…Seven healthy volunteers underwent diffusion-weighted magnetic resonance imaging (DWI) with five diffusion encoding schemes (monopolar, velocity-compensated (<i>M</i><sub>1</sub> = 0), acceleration-compensated (<i>M</i><sub>1</sub> = <i>M</i><sub>2</sub> = 0), 84%-<i>M</i><sub>1</sub>–<i>M</i><sub>2</sub>-compensated, 67%-<i>M</i><sub>1</sub>–<i>M</i><sub>2</sub>-compensated) at b-values of 50 and 800 s/mm<sup>2</sup> at a constant echo time of 70 ms. …”
-
1274
ADC maps of one volunteer.
Published 2023“…Seven healthy volunteers underwent diffusion-weighted magnetic resonance imaging (DWI) with five diffusion encoding schemes (monopolar, velocity-compensated (<i>M</i><sub>1</sub> = 0), acceleration-compensated (<i>M</i><sub>1</sub> = <i>M</i><sub>2</sub> = 0), 84%-<i>M</i><sub>1</sub>–<i>M</i><sub>2</sub>-compensated, 67%-<i>M</i><sub>1</sub>–<i>M</i><sub>2</sub>-compensated) at b-values of 50 and 800 s/mm<sup>2</sup> at a constant echo time of 70 ms. …”
-
1275
Absolute values of <i>M</i><sub>1</sub> and <i>M</i><sub>2</sub>.
Published 2023“…Seven healthy volunteers underwent diffusion-weighted magnetic resonance imaging (DWI) with five diffusion encoding schemes (monopolar, velocity-compensated (<i>M</i><sub>1</sub> = 0), acceleration-compensated (<i>M</i><sub>1</sub> = <i>M</i><sub>2</sub> = 0), 84%-<i>M</i><sub>1</sub>–<i>M</i><sub>2</sub>-compensated, 67%-<i>M</i><sub>1</sub>–<i>M</i><sub>2</sub>-compensated) at b-values of 50 and 800 s/mm<sup>2</sup> at a constant echo time of 70 ms. …”
-
1276
-
1277
Structure–Activity Studies of 1<i>H</i>‑Imidazo[4,5‑<i>c</i>]quinolin-4-amine Derivatives as A<sub>3</sub> Adenosine Receptor Positive Allosteric Modulators
Published 2022“…We previously reported 1<i>H</i>-imidazo[4,5-<i>c</i>]quinolin-4-amines as A<sub>3</sub> adenosine receptor (A<sub>3</sub>AR) positive allosteric modulators (PAMs). …”
-
1278
Structure–Activity Studies of 1<i>H</i>‑Imidazo[4,5‑<i>c</i>]quinolin-4-amine Derivatives as A<sub>3</sub> Adenosine Receptor Positive Allosteric Modulators
Published 2022“…We previously reported 1<i>H</i>-imidazo[4,5-<i>c</i>]quinolin-4-amines as A<sub>3</sub> adenosine receptor (A<sub>3</sub>AR) positive allosteric modulators (PAMs). …”
-
1279
-
1280